Avaliação de citocinas circulantes em pacientes com fibrose pulmonar idiopática em Bogotá
Barra lateral de artigos
Como Citar
Detalhes do artigo
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Conteúdo do artigo principal
Resumo
Objetivo: Identificar alterações nas concentrações plasmáticas de citocinas em pacientes com fibrose pulmonar idiopática e controles saudáveis residentes em Bogotá.
Métodos: Amostras de sangue periférico foram obtidas de 13 pacientes com mais de 60 anos de idade diagnosticados com FPI e 13 controles saudáveis. O plasma foi separado e armazenado a -20 °C. As citocinas foram medidas utilizando o Human TH1/TH2 Cytometric Bead Array (CBA). Este projeto recebeu aprovação do comitê de ética em pesquisa da Fundação Colombiana de Pneumologia.
Resultados: Pacientes com fibrose pulmonar idiopática (FPI) apresentaram níveis aumentados de citocinas como IL-4, IFN-γ e IL-6 em comparação com idosos saudáveis.
Conclusões: A inflamação crônica associada ao envelhecimento (inflammaging) tem sido relacionada ao desenvolvimento e à coexistência de diversas doenças crônicas não transmissíveis, que apresentam maior incidência após os 65 anos de idade. O envolvimento da imunidade adaptativa na patogênese da fibrose pulmonar idiopática (FPI) é conhecido, especificamente na resposta linfocitária Th1/Th2. A estimulação por IL-4 promove a mudança fenotípica para macrófagos M2 e células Th2, juntamente com a estimulação de ambientes profibróticos por células linfoides inatas do tipo 2 (ILC-2).
Referências
1. Departamento Nacional de Planeación. Visión Colombia 2050: Discusión sobre el país del futuro [Internet]. Planeta Colombiana S. A., editor. 2022 [Fecha de consulta: 2023 Sep 14]. Disponible en: https://colaboracion.dnp.gov.co/CDT/Prensa/Publicaciones/Documento_vision_colombia_2050.pdf
2. Ministerio de Salud y Protección Social de Colombia. Envejecimiento demográfico. Colombia 1951-2020: dinámica demográfica y estructuras poblacionales ministerio de salud y protección social oficina de promoción social [Internet]. 2013 [Fecha de consulta: 2023 Oct 24]. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/PS/Envejecimiento-demografico-Colombia-1951-2020.pdf
3. Departamento Administrativo Nacional de Estadística. Proyecciones demográficas con base CNPV 2018 [Internet]. 2021 [Fecha de consulta: 2023 Sep 17]. Available from: https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-y-poblacion/proyecciones-de-poblacion
4. Venosa A. Senescence in pulmonary fibrosis: between aging and exposure. Front Med (Lausanne). 2020;7:606462.
5. Kim NH, Sim SJ, Han HG. Immunosenescence and age-related immune cells: causes of age-related diseases. Arch Pharm Res. 2025;48(2):132-149.
6. Barbé-Tuana F, Funchal G, Schmitz CRR, Maurmann RM, Bauer ME. The interplay between immunosenescence and age-related diseases. Semin Immunopathol. 2020;42(5):545–557.
7. Wang Y, Dong C, Han Y, Gu Z, Sun C. Immunosenescence, aging and successful aging. Front Immunol. 2022.2:13:942796.
8. Ajoolabady A, Pratico D, Tang D, Zhou S, Franceschi C, Ren J. Immunosenescence and inflammaging: Mechanisms and role in diseases. Ageing Res Rev. 2024;101:102540.
9. Heukels P, Moor CC, von der Thüsen JH, Wijsenbeek MS, Kool M. Inflammation and immunity in IPF pathogenesis and treatment. Respir Med. 2019;147:79–91.
10. Mura I, Franco JF, Bernal L, Melo N, Díaz JJ, Akhavan-Tabatabaei R. A decade of air quality in Bogotá: a descriptive analysis. Front Environ Sci. 2020;8:65.
11. Mora AL, Rojas M, Pardo A, Selman M. Erratum: Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease. Nat Rev Drug Discov. 2017:16(11):755-772.
12. Sadek S, Kasem SM. Pulmonary haemodynamics and gasometric parameters associated with exercise induced oxygen desaturation in idiopathic pulmonary fibrosis. Egypt J Chest Dis Tuberc. 2017 Jul;66(3):505–507.
13. Lozo Vukovac E, Lozo M, Mise K, Gudelj I, Puljiz Ž, Jurcev-Savicevic A, Bradaric A, Kokeza J, Mise J. Bronchoalveolar pH and inflammatory biomarkers in newly diagnosed IPF and GERD patients: A case-control study. Med Sci Monit. 2014;20:255–261.
14. Sivakumar P, Ammar R, Thompson JR, Luo Y, Streltsov D, Porteous M, et al. Integrated plasma proteomics and lung transcriptomics reveal novel biomarkers in idiopathic pulmonary fibrosis. Respir Res. 2021;22(1):273.
15. Guiot J, Moermans C, Henket M, Corhay JL, Louis R. Blood Biomarkers in Idiopathic Pulmonary Fibrosis. Lung. 2017;195(3):273–280.
16. Galati D, De Martino M, Trotta A, et al. Peripheral depletion of NK cells and imbalance of the Treg/Th17 axis in idiopathic pulmonary fibrosis patients. Cytokine, 2014.66(2):119-126.
17. Kleiner G, Marcuzzi A, Zanin V, Monasta L, Zauli G. Cytokine Levels in the Serum of Healthy Subjects. Mediators Inflamm. 2013;2013:1–6.
18. Peng Y, Qi Q, Zhu M, Zhang Y, Bao Y, Liu Y. Plasma levels of 12 different cytokines correlate to PD-1 inhibitor combined chemotherapy responses in advanced non-small-cell lung cancer patient. Int Immunopharmacol. 2023;124:110888.
19. Guo S, Yin H, Zheng M, Tang Y, Lu B, Chen X, et al. Cytokine profiling reveals increased serum inflammatory cytokines in idiopathic choroidal neovascularization. BMC Ophthalmol. 2019;24;19(1):94.
20. Madera Rojas A, Cuervo Maldonado S, Sánchez R, Rincón JG, Bermúdez C. Cuantificación de citoquinas y su relación con la presencia de bacteriemia en leucemias agudas y neutropenia febril postquimioterapia. Rev Colomb Canc. 2017;21(3):152–159.
21. Chavda VP, Bezbaruah R, Ahmed N, Alom S, Bhattacharjee B, Nalla LV, Rynjah D, Gadanec LK, Apostolopoulos V. Proinflammatory Cytokines in Chronic Respiratory Diseases and Their Management. Cells. 2025;9;14(6):400.
22. Desai O, Winkler J, Minasyan M, Herzog EL. The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis. Front Med (Lausanne). 2018;5:43.
23. Blirando BioConsult K. A review of cellular senescence and senolytic drugs use in idiopathic pulmonary fibrosis [Internet]. 2020 [cited 2024 Mar 29]. Available from: https://www.researchgate.net/publication/339626771
24. Terekhova M, Swain A, Bohacova P, Aladyeva E, Arthur L, Laha A, et al. Single-cell atlas of healthy human blood unveils age-related loss of NKG2C+GZMB−CD8+ memory T cells and accumulation of type 2 memory T cells. Immunity. 2023;56(12):2836-2854.e9.
25. Liu Z, Liang Q, Ren Y, Guo C, Ge X, Wang L, et al. Immunosenescence: molecular mechanisms and diseases. Signal Transduct Target Ther. 2023;13;8(1):200.
26. Li X, Li C, Zhang W, Wang Y, Qian P, Huang H. Inflammation and aging: signaling pathways and intervention therapies. Signal Transduct Target Ther. 2023;8;8(1):239.
27. De Lauretis A, Sestini P, Pantelidis P, Hoyles R, Hansell DM, Goh NSL, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol. 2013;40(4):435–446.
28. Zheng B, Keen KJ, Fritzler MJ, Ryerson CJ, Wilcox P, Whalen BA, et al. Circulating cytokine levels in systemic sclerosis related interstitial lung disease and idiopathic pulmonary fibrosis. Sci Rep. 2023;13(1):6647.
29. Moss BJ, Ryter SW, Rosas IO. Pathogenic Mechanisms Underlying Idiopathic Pulmonary Fibrosis. Annu Rev Pathol. 2022;24;17(1):515–546.
30. Deng L, Huang T, Zhang L. T cells in idiopathic pulmonary fibrosis: crucial but controversial. Cell Death Discov. 2023;14;9(1):62.
31. Karande S, Sharma K, Kumar A, Charan S, Patil C, Sharma A. Potential role of biopeptides in the treatment of idiopathic pulmonary fibrosis. Health Sciences Review. 2023 Mar;6:100081.